Lipopolysaccharide-specific acyloxyacyl hydrolase by Munford, Robert S. & Hall, Catherine L.
United States Patent 19
Munfordetal.
      
  
[54] LIPOPOLYSACCHARIDE-SPECIFIC
ACYLOXYACYL HYDROLASE
[75] Inventors: Robert S. Munford; Catherine L.
Hall, both of Dallas, Tex.
[73] Assignee: The Board of Regents, The University
of Texas System, Austin, Tex.
[21] Appl. No.: 323,679
(22] Filed: Mar. 15, 1989
Related U.S. Application Data
[63] |Continuation-in-part of Ser. No. 53,044, May 22, 1987,
abandoned, whichis a continuation-in-part of Ser. No.
868,428, May 28, 1986, Pat. No. 4,929,604.
[S51] Int, CIS oeeee C12N 9/18; A61K 31/715;
C12P 19/26
[52] U.S. CD cece cecsesccsseseeeseeeeeeenenens 435/197; 435/84,
514/53; 514/54; 536/53; 424/94.61
[58] Field of Search................. 435/197, 84; 514/53,
514/54; 536/53; 424/94.61
[56] References Cited
U.S. PATENT DOCUMENTS
4,057,685 11/1977 McIntire ...... cc cssseescereeeeee 536/18
4,148,877 4/1979 Choayet al. .. weve 424/92
4,185,090 1/1980 MeIntire ....... cseeecceseseereee 424/92
4,242,270 12/1980 Aymeet al. ... w. 260/412.8
4,435,386 3/1984 Ribi et ab. oo. 424/177
4,436,727 3/1984 Ribi oe eeteectesee tree 424/177
4,436,728 3/1984 .Ribi et al. oc esereree 424/177
4,505,899 3/1985 Ribi et ab. ws eceseseseeeeee 514/8
4,505,900 3/1985 Ribi et al. oeseee 514/2
4,663,306 5/1987 Cantrell -....cccececsereessesceseene 5314/2
4,677,194 6/1987 Hao ou. ceseeeeeeees .. 530/350
4,719,202 1/1988 van Boeckelet al. . we. 514/61
OTHER PUBLICATIONS |
Kotani, et al. (1985), Infect. Immun., 49:225-237.
Takada, et al. (1985), Infect. Immun., 48:219-227.
Homma,etal. (1985) J. Biochem., 98:395-406.
Galanos,et al. (1984), Eur. J. Biochem., 140:221-227.
Rosner,et al. (1979), J. Biol. Chem., 254:5926-5933.
Gimber and Rafter (1969), Arch. Biochem. Biophys.,
135:14-20.
Munford and Hall (1985), Infect. Immun., 48:464-473.
Freudenberg,et al. (1984), Rev. Inf. Dis., 6:483-487.
Patent Number:
Date of Patent:
5,013,661
May 7, 1991
[11]
[45]
Kotani, et al. (1984), Infect. Immun., 485:293-296.
Sutherland (1977), “Surface Carbohydrates of the Pro-
karyotic Cells”, pp. 209-245.
Primary Examiner—Elizabeth C. Weimar
Assistant Examiner—Charles L. Patterson, Jr.
Attorney, Agent, or Firm—Arnold, White & Durkee
[57] ABSTRACT
An acyloxyacyl hydrolase from the human promyelo-
cyte cell line HL-60 has been found to specifically hy-
drolyze fatty acids from their ester linkages to hydroxy
groups of 3-hydroxyfatty acids, the latter being being
boundin turn to lipopolysaccharide glycosaminy]resi-
dues. The hydrolyzed fatty acids may include dodeca-
noic acid, tetradecanoic acid and hexadecanoic acid.
This enzyme showed a molecular weight by gel exclu-
sion chromatography between about 50,000 Daltons
and about 70,000 Daltons, and a molecular weight by
polyacrylamide gel electrophoresis with sodium dode-
cylsulphate, using reduced molecular weight standards,
of approximately 54,000 to 60,000 Daltons.
Altered bacterial lipopolysaccharide substantially with-
out fatty acids boundin ester linkage to hydroxy groups
of 3-hydroxyfatty acids covalently linked to a
glucosaminyl moiety of lipopolysaccharide lipid A are
produced. Since the structure of the lipid A moiety is
highly conserved, acyloxyacyl hydrolase may act on
lipopolysaccharide of many different pathogenic bac-
teria (for example Salmonella, Escherichia, Hemophi-
lus, and Neisseria).
Suchaltered bacterial lipopolysaccharide, having toxic-
ity reduced more than immunostimulatoryactivity, may
be therapeutically useful: (1) as vaccines to prevent
Gram-negative bacterial diseases by inducing antibodies
to lipopolysaccharide O-polysaccharide or R-core anti-
gens, (2) as antidotes to treat or prevent Gram-negative
bacterial sepsis (‘‘septic shock’’), or (3) as adjuvants to
enhance formation of antibodies to other antigens. the
acyloxyacy! hydrolase itself may be prophylactically or
therapeutically useful to detoxify endogenouslipopoly-
saccharide in patients with Gram-negative bacterial
diseases. The enzyme mayalso be used to remove toxic
lipopolysaccharide from therapeutic injectants.
11 Claims, 4 Drawing Sheets
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LIPOPOLYSACCHARIDE-SPECIFIC
ACYLOXYACYL HYDROLASE
The United States Government may haverights in 5
the present inveniion because the development was
partially supported by NIH grant RO1 AI18188 from
the Department of Health and Human Services.
This application is a continuation-in-part of U.S. pa-
tent application Ser. No. 053,044 filed May 22, 1987,
now abandoned, whichis a continuation-in-part of U.S.
patent application Ser. No. 868,428filed May 28, 1986
now U.S. Pat. No. 4,929,604.
BACKGROUND OF THE INVENTION 15
Thepresent invention relates to the detoxification of
bacterial endotoxin (lipopolysaccharide) by enzymatic
modificationofits lipid A moiety. The prophylactic and
therapeutic use of such detoxified endotoxins is also a
subject of the present invention.
Animals mount a complex array of inflammatory
responsesto tissue invasion by Gram-negative bacteria.
Many of these responses appear to be provoked by the
lipopolysaccharides (LPS) that are present in the bacte-
rial outer membrane. Muchevidence suggests that LPS
directly stimulates host cells such as macrophages, neu-
trophils, and endothelial cells, which then mediate the
inflammatory changes. Responses to LPS may be. toxic
(e.g. hypotension or coagulation disturbances) or bene-
ficial to the infected host (e.g. enhancementof antibody
formation, mobilization of phagocytes, acute phase pro-
tein synthesis, and others).
Typical Gram-negative bacterial lipopolysaccharides
{LPS) have 3 major structural regions: the O polysac-
charide, the R-core oligosaccharide, and lipid A (FIG. 35
1 and FIG.2). The structure of the O polysaccharideis
highly variable between organisms, even in the same
species, and its antigenicity serves as a basis for seroty-
ping the bacteria. The R region is a bridge between the
Q-antigen and lipid A; its structure is similar in most
Gram-negative bacteria. Antibodies to LPS (typically
directed to 0- or R-core antigenic sites) may promote
phagocytosis or killing of the bacteria, or they may
enhance removal of LPS from the bloodstream into
sites (liver, spleen) where the LPS are degraded. The
Q-antigen, which differs markedlyin LPS from differ-
ent bacterial genera, is the most antigenic componentof
the LPS. The R regionis also highly conserved andis
thought to contribute to the stimulatory potency of
LPS. Thelipid A moiety is remarkably similar in struc-
ture across a wide range of bacterial genera.
The lipid A of enteric bacteria (e.g. Salmonella, E.
coli) is a glucosamine disaccharide that is phosphory-
lated at positions 1 and 4’ and has 6 or 7 covalently-
linked fatty acids (FIG. 2). Four molecules of 3-hydrox-
ytetradecanoate (3-OH-14:0) are attached to the glucos-
amine disaccharide at positions 2, 3, 2’, and 3’; the hy-
droxyl groups of the 3-OH-14:0 residues at positions 2'
and 3’ (and sometimes 2) are substituted with normal
fatty acids (dodecanoate, tetradecanoate, hexadecano-
ate) to form acyloxyacyl groups. In 1983 the discovery
of a novel enzymatic activity was reported. This acy-
loxyacyl hydrolase activity, found in the granule frac-
tion of human peripheral blood neutrophils, selectively
removed someofthe nonhydroxylated acyl chains from
Salmonella typhimurium LPS (Hall and Munford (1983)
Proc. Nat. Acad. Sci. V 80, pp 6671-6675). It was
known that Dictyostelium discoideum (slime mold),
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whichutilizes Gram-negative bacteria as a major food-
stuff, contains enzymes that remove nonhydroxylated
and hydroxylated acyl chains from LPS (Rosneret al.
(1979) J. Biol. Chem. V 254, pp 5926-5933). The experi-
ments of Gimber and Rafter (Arch. Biochem. Biophys,
(1969), V 135, pp 14-20) had also suggested that deacy-
lation of LPSis carried out by intact neutrophils. These
papers, however, did not show purified enzymes.
Recent studies of the biological activities of chemi-
cally synthesized lipid A analogs and biosynthetic pre-
cursors of lipid A have provided valuable information
about structure-activity relationships (Galanos et al.
(1984) Eur. J. Biochem. V 140, p 221; Takada etal.
(1985) Infect. & Immun. V 48, p 219; Kotaniet al. (1985)
Infect. Immun. V 49, p 225; and Hommaetal. (1985) J.
Biochem. V 98, p 395). Lipid A analogs that lack non-
hydroxylated acyl chains are not reactive in the dermal
Shwartzman test and have reduced pyrogenicity, yet
they are nearly equipotent with complete lipid A in
various assays of immune stimulation such as B-cell
mitogenicity, adjuvanticity, and stimulation of macro-
phages to release prostaglandin E2 [PGE2]. However,
since the carbohydrate chain that is attached to lipid A
in LPS has been shown to have stimulatory potency
itself (Lebbar et al., 1986, Eur. J. Immunol. V. 16,
87-91) and to modulate (increase) the potency of lipid A
(Galanos, Reitschel, Luderitz, and Westphal, [1972]
Eur. J. Biochem. V. 31, 230-233; Kotani et al. [1985]
Infection and Immunity V. 49, 225-237), the effects of
acyloxyacyl hydrolysis on the biological activities of
LPS could not be predicted. The present invention
relates to the discovery that acyloxyacyl hydrolysis
detoxifies LPS without destroying the immunostimula-
tory activity.
SUMMARYOF THE INVENTION
An acyloxyacyl hydrolase isolated from human neu-
trophils has been found to specifically hydrolyze fatty
acids from their ester linkages to hydroxy groups of
3-hydroxyfatty acids, the latter being bound in turn
through their carboxylate functions to glucosaminyl
residues in the lipid A region of LPS. The hydrolyzed
fatty acids may include, for example, dodecanoic acid,
tetradecanoic acid and hexadecanoicacid. This enzyme,
purified from human promyelocytes, has the above
described specificity. Gel chromatography of the puri-
fied enyzme preparation showed a molecular weight
between about 50,000 Daltons and about 70,000
Daltons. Analysis of the enzyme by electrophoresis in
11 % polyacrylamide gels in the presence of sodium
dodecyl sulfate showed an apparent molecular weight,
using reduced molecular weight markers, of 54,000 to
60,000 Daltons. By the term “purified” as applied to this
enzyme, is meant greater than about 90% pure(prefera-
bly greater than about 95% pure) as judged by poly-
acrylamide gel electrophoresis.
Altered bacterial LPS substantially without fatty
acids bound in ester linkage to hydroxy groups of 3-
hydroxyfatty acids covalently linked to a glucosaminy]
moiety of LPS lipid A are produced as described
herein. By the term “substantially” as used herein to
define the extent of esterified fatty acid removal, is
meant greater than about 90% removal of fatty acids
normally esterified to the hydroxyl groups of the 3-
hydroxyfatty acid moieties. Said altered bacterial LPS
characteristically have bound 3-hydroxyfatty acids
with hydroxy functions at least substantially unesteri-
fied. Since the structure of the lipid A moiety is highly
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conserved, acyloxyacyl hydrolase may act on LPS of
many different pathogenic bacteria (those studied in-
clude Salmonella, Escherichia, Hemophilus, and Neisse-
ria).
Such altered bacterial LPS, having toxicity reduced
more than. immunostimulatory activity, may be thera-
peutically and/or prophylactically useful. Such thera-
peutic usefulness comprises use of the altered LPS (1) as
vaccines to prevent Gram-negative bacterial diseases by
inducing antibodies to 0-polysaccharide or R-core anti-
gens, (2) as antidotes to treat or prevent Gram-negative
bacterial sepsis (“septic shock”), or (3) as adjuvants to
enhance formation of antibodies to other antigens. The
acyloxyacyl hydrolase itself may be therapeutically or
prophylactically useful to detoxify endogenous LPS in
patients with, or at risk of, Gram-negative bacterial
diseases.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the general structure of Salmonella
LPS. LPSis a glycolipid that has a saccharide chain
covalently attached to a lipid (ipid A). LPS molecules
may have different lengths of saccharide chain. The
saccharide chain has two regions, O-antigen and R-core
as shown. Molecules that contain both O-antigen and
R-core are called “smooth,” while molecules that have
only R-coreare called “rough.” S-LPS refers to smooth
LPS(i.e., containing O-antigen). R-LPSrefers to rough
LPS. The R-coreis further subdivided, accordingto its
length, from Ra (complete core) to Re (only 2-keto-3-
deoxyoctulosonic acid (KDO)). The term “deep-
rough” LPS refers to Re LPS. SR-LPS have one O-
antigen repeat unit attached to the R-core. n =0 to
more than 50.
FIG. 2 shows the proposed general structure of en-
terobacterial lipid A. R= site of attachmentofthe poly-
saccharide chain. Arrowsindicate the site of action of
acyloxyacyl hydrolase.
FIG. 3 shows an SDS-polyacrylamide gel (11% poly-
acrylamide) analysis of purified enzyme. Lane A con-
tains molecular weight markers that had been reduced
by exposure to 2-mercaptoethanoland lane B contains
purified, unreduced acyloxyacyl hydrolase. The gel
was stained with silver. The apparent molecular weight
of the unreduced enzymeis 54,000 to 60,000 Daltons.
FIG. 4 showsbinding of the enzyme to LPS.A prep-
aration of partially purified enzyme was radiolabeled
with !25], The radiolabeled proteins were then incu-
bated with or without LPS for 1 hour at 22° C. Staphy-
lococci that had been coated with IgG antibodies to the
LPSwere then added, and after further incubation at 4°
C. the staphylococci were washed extensively and then
solubilized in SDS digestion buffer (2% SDS, 20%
glycerol) and the !25]-labeled proteins that bound to the
staphylococci were analyzed by SDS-polyacrylamide
gel electrophoresis and autoradiography. The lane
marked * contained the mixture of labeled proteins.
Lanes 1 through 4 contained staphylococci that were
incubated with the labeled proteins; LPS and anti-LPS
antibody were included in the incubation mixtures as
indicated. A single radiolabeled protein bound specifi-
cally to the staphylococci when both LPS and anti-LPS
were included (lane 3). This is the same band thatis
associated with enzymatic activity in all other purifica-
tion steps.
FIG. 5 showsthe time course for release of 3H-fattyacid, !'4C-glucosamine and 32P-phosphate from labeled
LPS in the presence of acyloxyacyl hydrolase.
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FIG. 6 showsthe effects of deacylation upon labeled
LPS samples subjected to electrophoresis in polyacryl-
amide gel with sodium dodecyl sulfate. Each lane con-
tained 0.5 ug LPS. The gel was treated with En3Hance
(New England Nuclear) and exposed to Kodak X-Omat
XAR-5 film at —70° C. Lane 1 contained S-LPS (about
1% deacylated); lane 2, S-LPS (25% deacylated); lane .
3, SRLPS (0.6% deacylated); lane 4, SR-LPS (15%
deacylated); lane 5, SR-LPS (28% deacylated); lane 6,
SR-LPS (65% deacylated with NaOH); lane 7, Rc-LPS
(1% deacylated); lane 8, Rc-LPS (20% deacylated);
lane 9, Rc-LPS (32% deacylated); lane 10, Rce-LPS
(65% deacylated with NaOH); and lane 11, S-LPS (1%
deacylated). The LPSin lanes 6 and 10 were deacylated
by treatment with NaOH, which hydolyzed all ester
bonds.
DESCRIPTION OF THE PREFERRED
EMBODIMENT
The present invention involves the use of a hydro-
lytic enzyme to detoxify bacterial lipopolysaccharide
(LPS or endotoxin). This detoxification involves the
hydrolysis of the ester bonds between nonhydroxylated
acyl functions and the hydroxy groupsof 3-hydroxymy-
ristoyl (3-hydroxytetradecanoate) or other 3-hydroxy
fatty acyl residues. These 3-hydroxymyristoyl functions
are, in turn, bound in ester or amide linkage to a D-
glucosaminyl disaccharidestructure of the LPSlipid A
moiety (see FIG. 2). The term acyloxyacyl hydrolase is
used here to refer to this enzymatic activity.
An acyloxyacyl hydrolase was purified from cells of
a human promyelocyte cell line, HL-60, and used to
deacylate LPS from S. typhimurium. The enzymatically
deacylated LPS lacked nonhydroxylated fatty acids but
retained phosphate, 3-hydroxymyristoyl residues, and
the polysaccharide chain. The effect of acyloxyacyl
hydrolysis on the biological activities of the LPS was
studied in several test systems. Loss of bioactivity in
these assays was directly related to the degree of deacy-
lation. Removal of approximately 95% of the nonhy-
droxylated fatty acids from the LPS had relatively
minor impact on B-cell mitogenicity (5- to 12-fold loss
of activity); intermediate effects on pyrogenicity and
Limulus lysate clotting activity, (10- to 20-fold loss of
activity); and major impact on preparing the skin for the
dermal Shwartzman reaction and on the stimulation of
human vascular endothelial cells (greater than 100-fold
loss of activity). The tissue toxicity of the LPS, mea-
sured in the Shwartzman reaction, was thus reduced at
least 10-fold more than the immunosiimulatory activity,
measured in the B-cell mitogenicity assay.
Acyloxyacyl hydrolase was released from the gran-
ule fraction of dimethylsulfoxide-induced HL-60 cells
by detergent solubilization and then purified using a
series of chromatographic procedures: blue agarose,
phenyl-Sepharose, hydroxylapatite, and cation ex-
change. From 36 grams ofcell lysate protein, approxi-
mately 6 micrograms of pure enzyme were obtained.
- The discoveries comprising the present invention
include the first description of a purified enzyme that
modifies the bioactivities of LPS. Acyloxyacyl hydro-
lase activity has been found in human neutrophils,
monocytes, and vascular endothelial cells, and in mouse
macrophages; the latter cells also contain mechanisms
for removing 3-hydroxymyristate residues from LPS.
Antibody-opsonized LPS undergo deacylation by both
neutrophils and macrophages, so acyloxyacyl hydro-
lases should act on the LPS in phagocytosed bacteria as
5,013,661
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well. In addition to Salmonella LPS, the enzyme also
deacylates LPS from otherbacteria (E. coli. Hemophilus
influenzae, Neisseria meningitidis, for example). Acylox-
yacy] hydrolases are mostlikely located in an acid intra-
cellular compartment(lysosomes or endosomes), where
deacylation of bacterial LPS would accompany the
digestion of other bacterial components. Neutrophils
are the front line of host defense against bacterial inva-
sion, yet they are short-lived in tissue and also appear to
regurgitate part of the material that they ingest; par-
tially deacylated LPS, released from the neutrophils,
may then interact with other host cells. It should be
emphasized that the intracellular fate of LPS is not
completely understood and thatexisting studies haveall
dealt with purified LPS, not the LPSin bacteria perse.
Presently unknown deacylases, acyl transferases, or
phosphatases may also process LPS intracellularly,
with a variety of potential effects on LPS bioactivity.
It should also be noted that the present inventors
have found acyloxyacyl hydrolase activity in the serum
of rabbits, mice, cows, pigs, chickens and man. Low
levels of activity are present in normal mouse and rabbit
serum; these levels can be increased 3- to 15-fold by
immunization of rabbits with Gram-negative bacteria or
by intravenous innoculation with LPS. The rabbit
serum acyloxyacyl hydrolase activity has a somewhat
higher pH optimum (5 to 6) than that found for human
neutrophil acyloxyacy! hydrolase (4.5 to 5.0). Although
normal human serum does not appear to have detect-
able acyloxyacy] hydrolase activity, low levels of activ-
ity have been found in the plasma of some patients with
Gram-negative bacterial bloodstream infection. These
preliminary studies suggest that animals respond to
Gram-negative bacterial immunization or infection by
increasing the acyloxyacyl hydrolase activity in their
blood. Presumably the enzyme(s) in blood mayeither
(1) bind to circulating LPS, targeting the LPS to be
taken up by phagocytic cells, where acyloxyacyl hydro-
lysis would occur, or (2) act on LPSin local tissue sites
ofinfection.
The major role of acyloxyacyl hydrolases in animals
may be to prevent LPS tissue toxicity. Remarkably,
acyloxyacyl hydrolysis has a much smaller negative
impact on the immunostimulatory potency of LPS,at
least as measured by assays such as B-cell mitogenicity.
Preservation of the immunostimulatory activities of
LPS would allow animals to derive benefits such as
immunepriming during health and the enhancement of
antibody formation during infections.
Thus, the acyloxyacyl hydrolase may be administered
as a therapeutic agent to patients subject to septic shack,
for example, due to infection by Gram-negative bac-
teria. The administration of therapeutically effective
amounts of the human acyloxyacyl hydrolase should
decrease the toxicity of the bacterial LPS while not
abolishing potentially helpful LPS biogenic effects such
as B lymphocytestimulation. A prophylactic use ofthis
enzyme may be appropriate where septic shock is a
distinct possibility. These uses may be by the usual
modes of administration such as by injection into veins,
arteries, or peritoneum. Whether administered thera-
peutically or prophylactically, exogenous acyloxyacyl
hydrolase would supplementthe patient’s own capacity
to produce the enzyme, increasing enzyme levels in
bloodand,possibly, in phagocytic cells. A normal 70 kg
man produces about 1 <10!! neutrophils per day. Sixty
micrograms of enzyme are contained in about 5x 10!!
HL-60 cells. Thus, if neutrophils and HL-60 cells pro-
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duce about the same amounts of enzyme, a 70 kg man
should produce 10-20 micrograms of acyloxyacyl hy-
drolase per day, only some of which is released into the
plasma. A likely effective therapeutic dose range of the
acyloxyacyl hydrolase would be from 10 to 100 micro-
grams per day. Pharmaceutically acceptable formula-
tions of the enzyme for administration include solutions
thereofin acceptable aqueousisotonic solutions prefera-
bly buffered at a physiological pH..
The antigenic structure of the polysaccharide regions
of LPSis not altered by acyloxyacyl hydrolysis. Enzy-
matic detoxification of the lipid A region of LPS with-
out destruction ofimmunostimulatory activity may thus
produce non-toxic LPS vaccines; the adjuvanticity of
the detoxified lipid A would help promote the forma-
tion of antibodies to the polysaccharide antigen(s). As
noted above, such antibodies may protect animals from
various Gram-negative bacterial diseases.
LPSthat have been detoxified by acyloxyacyl hydro-
lase may also be used therapeutically to antagonize the
toxic effects of LPS present in (or released from) infect-
ing bacteria. Enzymically deacylated LPS inhibits the
ability of native LPS to stimulate the expression by
human endothelial cells of a neutrophil-adherence fac-
tor (Pohlman, Munford, and Harlan, J. Exp. Med., V
165, p 1393, 1987). Deacylated LPS were inhibitory
when addedas long as 60 min after the native LPS. The
adherence of neutrophils to endothelial cells is thought
to play a role in the toxic effects of LPS.
A further use of the enzyme may be to reduce the
toxicity of therapeutic liquid injectants which may be
contaminated with LPS. Adding acyloxyacyl hydrolase
to the injectant and allowing the enzyme to enzymati-
cally hydrolyze ester bonds should detoxify LPS con-
tained therein.
A quantity of such injectant, contained in an isotonic
aqueous solution, for example, would be treated with
purified acyloxyacyl hydrolase. The enzyme should be
at a concentration between about 0.001 and 1.0 micro-
gramsperliter of injectant (preferably between 0.001
and 0.010); allowed to catalyze its specific ester hydro-
lysis to detoxify any LPS present (for example, for from
about one hour to a week). The enzyme may beat-
tached to a solid matrix for ready removal upon com-
pletion of such hydrolysis. The presence of detergent,
which might be afterward removed, may be used to
further enhance enzymeactivity.
The following examples are presented to illustrate
preferred embodiments of aspects of the present inven-
tion but are not intended to limit the scope of the inven-
tion unless otherwise specifically so stated in the claims
appended hereto.
EXAMPLE1
PURIFICATION OF ACYLOXYACYL
HYDROLASE
Cell source
HL-60 celis (American Type Culture Collection,
Rockville, MD, (ATCC)strain CCL-240) were propa-
gated in RPMI-1640 medium that contained 8% fetal
bovine serum (Hyclone), 10 units/ml penicillin G, and
50 ug/ml streptomycin. Typically, cultures of 16 liters
in spinner flasks were harvested after 4-5 days of
growth at 37° C.in an atmosphere of 5% CO2. Two or
three days before harvest, dimethylsulfoxide (1.25%,
vol/vol) was addedto the culture to induce the enzyme.
The cells were collected by centrifugation (500 xg, 10
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min, 4° C.), washed once with PBS (10 mM sodium
phosphate, 0.15 M sodium chloride, pH 7.1), and resus-
pended in 10 ml relaxation buffer (100 mM KCl, 3 mM
NaCl, 3.5 mM MgCl, and 10 mM HEPES,pH 7.4).
The cells were then disrupted by nitrogen cavitation
or by using several strokes in a Dounce homogenizer,
followed by centrifugation (478 xg, 5 min, 4° C.) to
pellet nuclei and unbrokencells.
Enzymepreparation
Granules containing the enzyme were sedimented. by
centrifugation at 20,000 x g for 10 min at 4° C. The
supernatant was recentrifuged and the combinedpellets
were resuspended in 27 ml relaxation buffer. Triton
X-100 was added (0.5 % vol/vol) and after the suspen-
sion sat for 10 minutes in an ice bath,distilled water was
added to bring the volume to 30 ml (Triton X-100 con-
centration of 0.05%). Phenylmethylsulfonylfluoride
(PMSF) and pepstatin were added (5 mM and 1 nM,
respectively), and the preparation was centrifuged at
100,000 ., g for 60 min at 4° C. The pellet was dis-
carded and glycerol. was added (20%, vol/vol) to the
supernatant, and the supernatant was frozen at —20° C.
With the exception of monoS chromatography, — all
subsequent purification steps were performed at room
temperature and the enzyme was stored between steps
at 4° C.
Blue agarose chromatography.
Disodium ethylenediaminetetraacetic acid (5 mM)
was added to the thawed supernatant, which was then
passed over a column of Blue Agarose, Type 1000
(Sigma). The column was washed sequentially with
running buffer (10 mM 2(N-morpholino) ethane sul-
fonic acid (MES)) pH 6.6, 0.01% Triton X-100, 20%
glycerol, 25 mM NaCl) that contained, in § column
volume, 0, 75 mM, and 150 mM KSCN.Elution of the
enzyme began with 150 mM KSCN;the remainder of
the enzyme was then eluted from the column with two
column volumes of 200 mM KSCN. Fractions that
contained enzyme werestored at 4° C.
Hydrophobic interaction chromatography
The Blue Agarose eluate was dialyzed against phe-
nyl-Sepharose column buffer (0.2 M [NH4]2SO4, 4 mM
NaH2PO4, 6 mM Na2HPO,4, 0.04% sodium azide,
0.01% Triton X-100, pH 6.8) at 4° C. for 3 hours (3
buffer changes), then applied to a column containing 10
to 25 ml Phenyl-Sepharose CL-4B. After application of
the sample, the column was washed with columnbuffer
until the 0.D.280 of the eluate reached a low plateau. A
linear gradient was then applied to the column,using
column buffer and elution buffer (75% ethylene glycol,
1.5 mM NaH2POg, 8.5 mM Na2HPOs, 0.04% sodium
azide, pH 7.2) in a ratio of one part column buffer to
twoparts elution buffer. Fractions (3 ml) were collected
and monitored for enzymeactivity and optical density
at 280 nm (0.D.280) The enzyme eluted with the first
half of the peak of 0.D.2g9 absorbance. Appropriate
fractions were pooled and stored at —20° C.
Hydroxyapatite (HPT) chromatography
The fractions from the preceding step were diluted
3-fold with HPT buffer (0.02 M sodium phosphate, pH
7.0, 0.04% sodium azide, .0.01% Triton X-100) and
applied to a 1.0xX4.0 cm column of hydroxyapatite
(Biorad HPT). Proteins were eluted with a gradient
from 0.02 to 0.4 M sodium phosphatein the samebuffer.
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The peak of enzymatic activity eluted at a phosphate
concentration of 0.2 M. Glycerol (30%, vol/vol) was
added and the fractions that contained the enzyme were
pooled and concentrated using a Centricon-30 centrifu-
gation device (Amicon).
Cation exchange chromatography
The concentrated HPT fractions were diluted 10-fold
in MonoSstart buffer (0.15 M sodium acetate, pH 4.5,
0.05% Triton X-100, 0.04% sodium azide, 2% taurine,
5% 2-propanol), centrifuged to remove particulates,
and applied through a 0.22 micron filter to a MonoS
column (Pharmacia). Using the FPLC system (Phar-
macia), proteins were eluted from the column using
MonoSstart buffer with a gradient of 0-1.0 M NaCl.
The peak of enzymatic activity eluted at a NaCl con-
centration of approximately 0.27-0.3 M. Glycerol (28%
vol/vol) and 0.3 volumes of sodium phosphate (400
mM)were addedto the peak fractions before they were
pooled and concentrated as described above.
Theprotein composition of the final preparation was
analyzed by polyacrylamide gel electrophoresis using
sodium dodecyl sulfate. When stained with silver, the
unreduced material showed a single band at an apparent
molecular weight of 54,000 to 60,000 Daltons (FIG.3).
After reduction with 2-mercaptoethanol to break disul-
fide bonds, the major protein band had an apparent
molecular weight of 48,000 to 52,000 Daltons. Lower
molecular weight (10,000 to 20,000 Daltons) compo-
nents of the reduced enzyme were detected using 2-
dimensional(first dimension, unreduced; second dimen-
sion, reduced with 2-mercaptoethanol) electrophoresis
of enzymeprotein that had been labeled with 1251. A
protein with the same electrophoretic properties and
subunit structure as the enzyme was shownto bind to
LPS, the substrate for the enzyme (FIG. 4).
A summaryofthe purification procedure is provided
in Table 1.
TABLE1
PURIFICATION OF ACYLOXYACYL
HYDROLASE FROM HL-60 CELLS
 
Recovery
(cumulative %) Specific activity
Enzyme Activity/ug
Procedure Protein activity protein
Post-nuclear lysate 100 100 1
Triton X-100 soluble, 13.1 80.5 6
100,00 x g supernate
of granule fraction
Blue Agarose peak 0.62 62.2 98
Phenyl-Sepharose peak 0.04 50.7 1,264
Hydroxylapatite peak 0.0027 32.9 12,100
monoS peak 0.000017 10.1 578,693
 
From 36 grams of post-nuclear lysate, approximately 6.5 micrograms of pure
enzyme were obtained.
Alternative cell source
The above methods have also been used to purify
acyloxyacyl hydrolase from human peripheral blood
neutrophils. The properties of the enzymatic activity
obtained from the two sources are essentially identical.
Because it may be morereadily obtained in larger quan-
tities, the HL-60 cell enzyme has been used for the
studies described in examples 2, 3, and 4.
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EXAMPLE2
ACYLOXYACYL HYDROLASE ACTIVITY
UPON LPS
Incubation. conditions
Biosynthetically radiolabeled LPS were prepared
from Salmonella typhimurium grownin the presence of
3H-acetate and N-acetyl-1-[!4C]-glucosamine (incorpo-
rated into fatty acids and the glucosamine backbone,
respectively, of the lipid A region). Acyloxyacyl hydro-
lysis was followed by measuring the release of 3H-fattyacids from the }4C-glucosamine-labeled LPS backbone.
Double-labeled quantities of GH/14C) LPS (5 ug)
were incubated at 37° C. with purified enzyme(10 ul) in
a reaction mixture (0.5 ml) that contained 1 mg/ml fatty
acid-free bovine serum albumin (BSA) (Sigma), St.
Louis Mo), 5 mM CaCla, 0.5% (vol/vol) Triton X-100,
and 20 mM Tris-citrate, pH 4.8. The reaction was
stopped at the desired time points by precipitating the
LPSand BSA with 1.2 ml 95% ethanol. The precipitate
was collected by centrifugation (12,000 x g, 10 min, 4°
C.) and washed nnce with 1.0 mi 80% ethanol. The
precipitates were suspended in 0.5 ml normalsaline and
stored at —20° C. Aliquots of the precipitates and su-
pernatants were counted and the percentage of each
radiolabel that appeared in the supernatant was calcu-
lated. 32P-labeled S. typhimurium Rc LPS,prepared by
growing strain PRX20 in a low phosphate medium that
contained 32PQ4 (orthophosphate, New England Nu-
clear, Boston, MA), were incubated in parallel and
precipitated in the same way; 32PQ4, when incubated in
parallel and processed identically, was completely re-
covered in the ethanol supernatant.
Fatty Acid Analysis.
LPS were deacylated- and precipitated with ethanol,
and the ethanol-water supernatant was dried under N2.
The 3H-fatty acids were extracted into chloroform/me-
thanol (2/1). Unincubated LPS and the deacylated LPS
in the ethanol precipitate were hydrolyzed and the
liberated fatty acids were extracted into chloroform.
Recovery of radioactivity at each step was greater than
85%. The samples were analyzed by one-dimensional
TLCusing Silica gel G plates (Analtech). The solvent
system. was petroleum ether/diethyl ether/acetic acid
(70/30/1). The spots were scraped from the plate and
radioactivity. measured (84-96% recovery of added
radioactivity). Values reported are the means of dupli-
cate determinations.
Deacylation of LPS.
Thetime course of the deacylation reaction is shown
in FIG. 5. 3H-fatty acids were released from the LPS
over time, while neither '4C nor 32P (present in 32P-
labeled S. typhimurium LPS that was treated with en-
zymein parallel with the 3H/!4C LPS) was released
significantly. The reaction reached an apparent maxi-
mum when approximately 32% of the 3H-fatty acids
were extracted from the LPS; since 35% of the 3H-
counts in this preparation were in nonhydroxylated
fatty acids (NFA), 32% deacylation was consistent with
nearly complete removal of these residues. This conclu-
sion was supported by analysis of the fatty acid compo-
sition of the substrate LPS and the reaction products;
65% of the 3H-fatty acid counts in the LPS were in
3-OH-14:0 and 35% were in NFA, whereas the deacy-
lated fatty acids that were released from LPS were
almost entirely (94%) nonhydroxylated and 95% of the
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fatty acids in the partially deacylated LPS were 3-OH-
14:0.
As shownin FIG. 6, sampies of acylated and deacy-
lated LPS were solubilized in sample buffer and sub-
jected to electrophoresis in polyacrylamide gel with
sodium dodecyl sulfate (SDS-PAGE).
Enzymatic deacylation produced an increase in the
migration of the LPS in SDS-PAGE,consistent with a
reduction in the size of the molecules (FIG. 6). This
increase in migration was less than was observed for
LPSthat had been treated with alkali, which removes
all four ofthe ester-linked fatty acids from lipid A (com-
pare lanes 5 and 6, 9 and 10). Preservation of the origi-
nal ladder pattern (which reflected the presence of
molecules with different numbers of 0-repeat units in
the deacylated smooth LPS (lanes 1 and 2) indicated
that the polysaccharide chain was not removed by en-
zymatic treatment.
Taken together, the evidence shows that the only
modification in the enzymatically treated molecules was
the loss of NFA.
EXAMPLE3
CHARACTERISTICS OF ACYLOXYACYL
HYDROLASE FROM HUMAN NEUTROPHILS
Enzymatic activity was approximately 500,000 fold
increased in the MonoS peak fraction relative to the
post-nuclear homogenate. The enzymatic activity was
abolished by heating for 10 min at 80° C. but was not
inhibited by EDTA (10 mM), PMSF (5 mM), pepstatin
(1 mM), para-hydroxymercuribenzoate (0.2 mM), so-
dium fluoride (50 mM), TPCK (0.1 mM), TLCK (0.1
mM), or soybean trypsin inhibitor (10 ug/ml). Calcium
chloride (5 -10 mM)and Triton X-100 (0.5 % vol/vol)
were required for maximal activity. Sodium deoxycho-
late (0.1% wt/vol) and 2-mercaptoethanol (100 mM)
inhibited the reaction. The enzyme adhered to solid-
phaselentil lectin and wheat germ lectin. On gelfiltra-
tion chromatography, the enzymatic activity eluted as a
single peak with an approximate size of 50,000 to 70,000
Daltons. The prior exposure of the preparation to Tri-
ton X-100 mayartifactually influence this molecular
weight estimate. The enzyme also bound to LPS,its
substrate. To identify the molecular weight of the LPS-
binding material, impure preparations of enzyme that
contained approximately 5 protein bands on silver-
stained SDS-polyacrylamide electrophoresis gels were
radioiodinated and subjected to additional analyses.
Whenthe radioiodinated mixture was incubated with
LPS, and the LPS was then adsorbed from solution
using solid-phase anti-LPS antibodies, a single radioac-
tive protein was found to bind to the LPS. This band
had an apparent molecular weight on SDS-PAGE
(11% polyacrylamide, using reduced molecular weight
markers) of approximately 54,000 to 62,000 Daltons; the
same radioactive band co-eluted with enzymatic activ-
ity and had an apparent size of 50,000-70,000 on size
exclusion chromatography (Superose 12, Pharmacia
Labs., Inc., Piscataway, N.J.). When reduced with 2-
mercaptoethanol, the LPS-binding protein and the radi-
oiodinated pure enzyme both contained major compo-
nents at approximately 50,000 Daltons and minor com-
ponents of approximately 10,000 to 20,000 Daltons.
Totest the ability of the purified enzyme to deacylate
LPS from different gram-negative bacteria, radiola-
beled LPS were prepared from S. typhimurium and E.
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coli (2 members of the family Enterobacteriaceae), and
from 2 distantly related species, Neisseria meningitidis
- (family Neisseriaceae) and Hemophilusinfluenzae (family
Brucellaceae). In each instance,. the enzyme preferen-
tially removed the non-hydroxylated fatty acids from
the LPS.Since acyloxyacyllinkages have been found in
the LPS from all medically important Gram negative
bacteria studied,it is likely that susceptibility of LPS to
acyloxyacyl hydrolase is a general phenomenon.
The purified enzyme did not contain measurable
amounts of phosphatases acting to dephosphorylate
either S. typhimurium Rc LPS or deep-rough E. coli
LPS. The absence of such phosphatase activity is pre-
ferred for practices of the present invention.
A series ofsamples that contained increasing amounts
of acyloxyacyl hydolase activity was found to have
decreasing amounts of hydrolytic activity toward me-
thylumbiliferyl oleate, a substrate for the enzyme, acid
lipase. Additionally, it was found that acyloxyacyl hy-
drolase did not show hydrolytic activity toward choles-
terol esters, of toward glycerol trioleate, further distin-
guishing acyloxyacyl hydrolase from more common
hydrolytic enzymes.
EXAMPLE4 |
ALTERATION BY ACYLOXYACYL
HYDROLASEOF LPS BIOACTIVITIES
R-LPS (rough LPSwith short polysaccharide chain)
from S. typhimurium was treated with acyloxyacy] hy-
drolase purified as described herein.
The deacylation ofLPS was performed by incubating
coxstant amounts of R-LPS and acyloxyacyl hydrolase
for different time periods to produce different degrees
of deacylation. Background deacylation (LPS incu-
bated without enzyme) of 0.5-2.2% was subtracted
from each value. Controls in each bioactivity assay
included the reaction mixture and the reaction mixture
that contained enzyme but no LPS;these controls were
always negative. ,
The effects of acyloxyacyl hydrolysis on the bioac-
tivities of the LPS were examined in six assays. The
dermal Shwartzman reaction and the rabbit pyrogen
test were used to measure in vivo toxicity. The mouse
spleen cell (B-lymphocyte) mitogenicity assay, the stim-
ulation of murine macrophagesto release prostaglan-
dins, and the stimulation of human vascular endothelial
cells to express neutrophil-adherence factor were used
to measure in vitro bioactivities of LPS.
A dermal Shwartzman reaction was performed by
intradermal injection of LPS or enzymically deacylated
LPS into New Zealand white rabbits. Twenty-two
hourslater, the animals were given an intravenous dose
of R-LPS (2-4 ug/kg). The dermal lesions were scored
4 to 6 hours later by two persons not knowing the iden-
tity of the samples. The average results from two rabbits
are presented in the second and third columns of Table
2.
Thermal response index (TRI) for LPS preparations
was determined by injecting a New Zealand white rab-
bit weighing 3-4 kg with an intravenous dose of LPS.
Temperature was monitored with a rectal probe and
recorded every 10 min. The Thermal Response Indexis
the integrated product of the temperature above base-
line (° C.) and time (degree-hours). (Zimmer et al.
(1981) Peptides, V 2, p 413) Each dose was tested in 3 or
4 rabbits.
B-cell proliferation was measured byfirst incubating
LPSpreparations with murine splenocytes in 98-well
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microtiter plates as described by Wannemuehleret al.
(1984) J. Immunol. V 133, p 299. After 24 hours, meth-
yl-[3H] thymidine (0.5 uCi) was added to each well. The
amount of radioactivity incorporated into each cell
culture was measured 18 hours later. Each LPS was
tested in four 5-fold dilutions; probit analysis of the
results indicated the amount of each preparation that
produced half-maximal stimulation of B-cell prolifera-
tion. The maximal stimulation index (3H-radioactivity
in stimulated cells / 3H-radioactivity in unstimulated
cells) in the two experiments shown in Table 2 was 30
and 29, respectively.
The fourth assay was the Limulus lysate test, an in
vitro clotting: assay for LPS. Limulus lysate clotting
was measured using 50 ul lysate (Cape Cod Associates,
Woods Hole, MA)that contained 0.8 mg/ml n-benzoyl-
L-valylglycyl-L-arginine PNA (Vega Biochemicals,
Tucson, AZ) and 50 ul test sample. After incubation for
55 min at 37° C., 0.7 ml 40% acetic acid was added to
each tube and the absorbance at 405 nm was measured.
The values shown were derived b applying the results
of 10-fold dilutions of test samples to a standard curve
that was constructed with Rc LPS, with normalization
to a starting concentration of 10 ug/ml. Dilutions were
performed in pyrogen-free water. Each value is the
mean of duplicate determinations that differed by less
than 10%. Similar results were obtained in two addi-
tional experiments.
The stimulation of murine macrophages to relaase
prostaglandin E2 was also used as an index of immunos-
timulatory activity. Thioglycolate-elicited C3H/HeN
mouse macrophages were incubated with acylated and
29%-deacylated LPS for 40 hours at 37° C. as described
by Munford and Hall (1985) Infection and Immunity, V
48, pp. 464-473. PGE)levels in the cell supernatants
were measured by radioimmunoassay (Campbell et al.
(1980) Hypertension, V 2, pp 472-476).
LPSstimulates vascular endothelial cells to express
cell-surface factor(s) that promote the adherence of
neutrophils to the endothelial cell surface. This activity
is thoughtto play a role in the toxicity of LPS as well as
in the attraction of neutrophils to tissue sites of bacterial
infection. In collaborative studies, the ability of LPS
and deacylated LPSto stimulate the adherence of 5!Cr-
labeled human neutrophils to monolayers of human
umbilical vein endothelial cells was tested (PohIman et
al. (1987), J. Exp. Med., V 165, p 1393).
Theeffects of acyloxyacyl hydrolysis on the bioac-
tivities of LPS in these assays were studied in two ways.
First, the impact of maximal LPS deacylation (30-32%
loss of 3H-fatty acids) was assessed in each bioassay.
Second, the dose-response relationship (degree of
deacylation vs. loss of bioactivity) was studied in three
of the assays.
Impact of Maximal Deacylation.
An intradermal injection of LPS, when followed 20
to 24 hours later by an intravenous injection of LPS,
produces hemorrhagic necrosis of the skin at the intra-
dermal injection site (dermal Shwartzman reaction).
Maximally deacylated LPS (32% loss of 3H-fatty acids)
did not prepare the skin for the reaction at doses as high
as 10 ug, whereas LPSthat had been incubatedin reac-
tion mixture without enzyme produced hemorrhage
(4—5 mm diameter) and induration at doses of 0.1 ug; the
reduction in toxicity was thus 100-fold or greater.
Deacylated LPS werealso substantially less pyrogenic
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in rabbits than fully acylated LPS. Intravenous doses of
62 ng/kg of acylated and 32%-deacylated LPS pro-
duced mean thermal response indices of 12.0+2.5
(S.D.) and 5.0+ 1.0, respectively, while the indices with
25 ng/kg doses were 8.51.9 and 2.81.1, respec-
tively. Deacylation of 32% of the 3H-fatty acids was
associated with approximately 100- to 500- fold loss of
stimulatory potency toward human umbilical vein en-
dothelial cells 20-fold loss of activity in the Limulus
test, a 5- to 12-fold reduction in B-cell mitogenicity, and
a 10- to 20-fold reduction in the release of PGE2 by
thioglycolate-elicited murine macrophages. Taken to-
gether, these results indicated that maximally deacy-
lated LPS wereat least 10-fold less toxic (as measured
in the dermal Shwartzman test) than they were im-
munostimulatory (as measured by the B-cell mitogenic-
ity test).
Dose-response.
Table 2 showsthe relationship between the degree of
deacylation and the loss of bioactivity for three of the
assays. In each assay, loss of activity wasdirectly re-
lated to the degree of deacylation.
TABLE2
_0
20
14
bound to a lipopolysaccharide glycosaminyl residue
without hydrolyzing ester or amide bonds between the
3-hydroxyfatty acid and the lipopolysaccharide
glucosaminyl residues.
2. The composition of matter of claim 1 wherein the
acyloxyacyl hydrolase is obtained from human neutro-
phils or human promyelocyte cell line HL-60.
3. The composition of matter of claim 1 wherein the
acyloxyacyl hydrolase is obtained from human promy-
elocyte cell line HL-60.
4. The composition of matter of claim 1 wherein the
fatty acids are at least one of dodecanoic acid, tet-
radecanoic acid or hexadecanoic acid.
5. The composition of matter of claim 1 wherein the
acyloxyacyl hydrolase is obtained from human neutro-
phils or the human promyelocytecell line HL-60 andis
capable of hydrolyzing ester bonds between fatty acids
or 2-hydroxyfatty acids and a hydroxyl function of a
3-hydroxyfatty. acid bound to a lipopolysaccharide
glucosaminyl residue.
6. The composition of matter of claim 1 wherein the
acyloxyacyl hydrolase has a molecular weightas deter-
mined by gel exclusion chromatography of between
EFFECTS OF DEACYLATION ON LPS BIOACTIVITIES
Dermal Shwartzman Dose for half-maximal
 
Reaction” B-cell Proliferation? Limuluslysate
Deacylation of LPS! (0-4+) (ug/m) Activity*
{(%) Rabbit 1 Rabbit 2 Expt | Expt 2 (ug/m!)
0 34+ 3+ 0.024 0.016 6.7
11-15 4+ 2+ 0.055 0.08 4.6
20~22 2+ 2+ 0.087 NT 3.4
29 1+ 0 0.100 NT 1.3
32 0 0 0.14 0.18 0.4
1GH-fatry acids released/total 3H-fatty acids in LPS) x 100.
2Constant amounts (2.5 ug) of R-LPS that had undergonedifferent degrees of deacylation were injected
intradermally in New Zealand White rabbits. 0 = no reaction; 1+ = less than or equal to 4 mm hemorrage;
2+ = 5-9 mm hemmorhage; 3+ = 10-15 mm hemorrhage; 4+ = greater than 15 mm hemorrhage.
3Single-cell suspensions of C3H/HeN mouse spleen were incubated with LPS in 96-well microtiter plates and
incorporation of 3H methyl thymidine measured.
4Limulus lysate clotting was measured using 50 u! lysate that contained 0.8 mg/ml n-benzoy]-L-valyl-glycyl-L-
arginine PNA and 50 ul test sample.
In summary, acyloxyacyl hydrolysis greatly reduced
the tissue toxicity of LPS while preserving relatively
more of the immunostimulatory activity. This conclu-
sion was consistent with the results of experiments,
discussed in Background, that used lipid A analogs to
evaluate the stimulatory role of acyloxyacyl groups.
Acyloxyacyl hydrolysis makes possible the detoxifica-
tion of LPS from many different bacteria, including
LPS with long polysaccharide chains. The reduction in
bioactivity was directly related to the degree of deacy-
lation (Table 1).
Changes may be madein the construction, operation
and arrangement of the various elements, steps and
procedures described herein without departing from the
concept and scope of the invention as defined in the
following claims.
Whatis claimed is:
1. A composition of matter comprising acyloxyacyl
hydrolase which is at least 90% pure, said hydrolase
being capable of hydrolyzing ester bonds between fatty
acids and a hydroxyl function of a 3-hydroxyfatty acid
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about 50,000 Daltons and about 70,000 Daltons.
7. The composition of matter of claim 1 wherein the
acyloxyacyl hydrolase is essentially devoid of hydro-
lytic activity toward cholesterol esters, glycerol triole-
ate, and phosphoryl groups of lipopolysaccharide.
8. The composition of matter of claim 1 wherein the
acyloxyacyl hydrolase is obtained from serum or pe-
ripheral blood neutrophils.
9. The composition of matter of claim 1 wherein the
acyloxyacyl hydrolase has a molecular weight a deter-
mined by 11% polyacrylamide gel electrophoresis with
sodium dodecylsulfate, using reduced molecular weight
standards, of approximately 54,000 to 60,000 Daltons.
10. The composition of matter of claim 9 wherein the
acyloxyacyl hydrolase has a binding affinity for lipo-
polysaccharide.
11. The composition of matter of claim 9 wherein the
acyloxyacyl hydrolase is obtained from serum, periph-
eral blood neutrophils or human promyelocyte cell line
HL-60.
* * * & *€
  
UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION
PATENTNO. : 5,013,661 Page 1 of 2
DATED May 7, 1991
INVENTOR(S): Robert S. Munford, et al.
it is certified that error appears in the abave-identified patent and that said Letters Patent is hereby
corrected as shown below:
At
At
At
At
At
At
At
column 4, line 50, delete “immunosiimulatory" andinsert ~--immunostimulatory-- therefor.
column 7, line 21, delete "-. g" and insert -~x g--therefor.
column 7, line 36, delete "7/8" and insert --1/3--therefor.
column 7, line 58, after '(0.D.59,)' and before'The enzyme' insert --.--.
column 9, line 22, delete "nnce" and insert--once-- therefor.
column 11, line 21, after ‘esters' and before', glycerol' insert --or toward-- and delete"of toward".
column 12, line 21, delete "b" and insert --by--therefor.  
  
UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION
PATENTNO. : 5,013,661 Page 2 of 2
DATED : May 7, 1991
INVENTOR(S): Robert S. Munford, ét al.
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
corrected as shown below:
In claim 9, column 14, line 51, after ‘molecularweight' and before 'determined' delete "a" andinsert -~-as-- therefor.
Signed and Sealed this
Twenty-seventh Day of October, 1992
Attest:
DOUGLAS B. COMER
Attesting Officer Acting Commissioner of Patents and Trademarks  
